TL;DR
In a 31-patient phase II trial, brepocitinib was associated with substantial improvement in cutaneous sarcoidosis activity scores after 16 weeks, while the placebo group showed no decrease. The findings are promising but do not establish the drug as an approved treatment for sarcoidosis; a phase III trial is underway, with primary results expected at the end of 2028.
Brepocitinib improved skin disease activity in a small phase II trial involving people with cutaneous sarcoidosis, according to findings reported at the American College of Rheumatology annual meeting and published in JAMA Dermatology. Participants taking either of two doses had an average 22-point reduction in disease activity scores after 16 weeks, compared with no average reduction among those given placebo; a larger phase III study is now underway to test the drug further.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The trial enrolled 31 patients, randomly assigning them to 45 mg or 15 mg of brepocitinib daily, or placebo. The primary measure was change in the Activity component of the Cutaneous Sarcoidosis Activity and Morphology Instrument, known as CSAMI-A. Investigators reported that both active-dose groups had average reductions of about 22 points at week 16, exceeding the study’s five-point threshold for clinical relevance. The placebo group had no decrease.
Some outcomes favored the higher dose. All patients taking 45 mg had at least a 10-point CSAMI-A reduction, compared with 73% taking 15 mg and 14% receiving placebo. A CSAMI-A score below 5, which the study defined as functional remission, was reached by 62% in the higher-dose group, 46% in the lower-dose group and none in the placebo group. All five high-dose participants with lupus pernio, a form involving discolored, raised lesions often affecting the face, had at least a 10-point reduction.
Participants taking brepocitinib also had substantial improvement in skin-related quality of life, the study team reported, while the placebo group’s scores worsened. One participant in each trial arm stopped treatment because of adverse events; none of those events was rated serious. Reported issues included a creatine kinase elevation and anemia in separate patients taking the higher dose. The study did not record the listed events of special interest, which included cardiovascular events, viral reactivation, liver enzyme elevations, blood clots and malignancies.
A Potential Option for Difficult Skin Disease
The results matter because cutaneous sarcoidosis can be difficult to control, and established treatments do not work reliably for everyone. The trial’s separation between brepocitinib and placebo across the primary measure and several other outcomes offers a reason to study the drug in a larger group. It does not, however, show that the treatment will work as well in routine care or establish its long-term safety.
The findings are especially relevant to patients with visible or persistent lesions, including lupus pernio, and to clinicians weighing options after other therapies have not helped. But the small number of participants means the response rates should be read as early evidence, not as a prediction for every patient. The study was also focused on skin disease, so its results do not establish whether brepocitinib improves sarcoidosis affecting the lungs, joints or other organs.
Products Worth Considering

Oral-B iO Series 7 Deep Clean + Protect Rechargeable Electric Toothbrush, Black, with 2 Brush Heads and Charging Travel Case

Levoit Vital 100S-P Air Purifier with Washable Pre-Filter

Withings Body Scan Smart Scale
As an affiliate, we earn on qualifying purchases.
Why Researchers Are Testing Brepocitinib
Reported treatment options for cutaneous sarcoidosis include corticosteroids, hydroxychloroquine, methotrexate and tetracyclines. The source report describes these approaches as inconsistently effective; relapses are common among some patients who respond to corticosteroids. Tumor necrosis factor inhibitors have also been recommended as a later treatment option, but the report says the supporting evidence is limited and earlier case series described adverse effects, treatment discontinuations and relapses.
Researchers have consequently explored drugs that affect Janus kinase pathways. Tofacitinib and upadacitinib have been reported in small case reports or series, and a single-patient report described a favorable result with deucravacitinib. Those reports are not equivalent to a controlled trial. Brepocitinib, a dual TYK2/JAK1 inhibitor, was approved by the FDA in August 2026 for dermatomyositis, according to the source report; that approval is for a different condition and does not make it an approved sarcoidosis treatment.
In the phase II trial, participants could continue conventional non-targeted treatments. Oral steroids were withdrawn over the first eight weeks, and topical steroids were stopped at randomization. The groups differed in average disease duration: about 10 years in the placebo and high-dose groups and about four years in the low-dose group. These details matter when interpreting results from a small study.
““I imagine many patients would get it as first line,””
— Misha Rosenbach, MD, of the University of Pennsylvania, speaking after his conference presentation
Questions Beyond the 16-Week Results
The phase II study was small and lasted 16 weeks, so it cannot settle how durable the skin improvements are, how the drug performs in a broader patient population, or what risks may emerge with longer use. The reported results also do not show whether the two doses differ reliably on the primary outcome; investigators found no difference between doses for that measure.
It remains unclear whether brepocitinib will improve sarcoidosis affecting organs beyond the skin. The study was designed around skin outcomes, and researchers said the larger trial is expected to examine other manifestations. The available report does not provide enough evidence to determine how the medicine would compare directly with existing treatments or what its eventual place in care might be.
Phase III Trial Sets Next Milestone
A larger phase III trial is underway, with the 45 mg daily dose selected for study as a potential approval dose, according to Rosenbach. Priovant Therapeutics expects the trial’s primary results at the end of 2028. Those findings should offer a more reliable test of whether the phase II improvements hold in a larger group and provide further safety information.
Until then, brepocitinib remains an investigational option for cutaneous sarcoidosis. The phase II findings are evidence of potential benefit, not confirmation of efficacy for all patients or approval for this condition. Further trial results will also help clarify whether the drug affects symptoms beyond skin disease.
Key Questions
Did brepocitinib improve cutaneous sarcoidosis in the trial?
In the 31-person phase II trial, both brepocitinib dose groups had an average 22-point reduction in CSAMI-A scores after 16 weeks. The placebo group had no average reduction. A larger trial is needed to test whether the result holds.
Is brepocitinib approved for cutaneous sarcoidosis?
No approval for sarcoidosis was reported. The source says the FDA approved brepocitinib for dermatomyositis in August 2026. Its use for cutaneous sarcoidosis is still being studied.
How many people took part in the phase II study?
The trial enrolled 31 patients, assigned to 45 mg brepocitinib, 15 mg brepocitinib or placebo. The small sample limits how confidently the results can be applied to a wider population.
Did the study show improvement in lung or joint sarcoidosis?
The reported study focused on skin outcomes. Rosenbach said the available studies had focused on skin and did not establish effects on pulmonary or joint symptoms; the phase III study is expected to examine other manifestations.
When will more trial results be available?
Priovant Therapeutics expects the phase III trial’s primary results at the end of 2028, according to the source report.
Source: medpagetoday.com
